Philipp S, Menter A, Nikkels AF, et al. - Researchers conducted this phase 3, open‐label, single‐arm, multicenter study to assess the safety and effectiveness of ustekinumab in pediatric psoriasis patients (≥ 6 to < 12 years of age). For this investigation, individuals received weight‐based dosing of ustekinumab (< 60 kg: 0.75 mg/kg; ≥ 60 to ≤ 100 kg: 45 mg; >100 kg: 90 mg) administered by subcutaneous injection at weeks 0/4, then every‐12‐weeks through week 40. In total, 44 individuals (median age, 9.5 years) received at least one dose of ustekinumab. Data reported that the incidence of anti‐drug antibodies was 9.5%. In pediatric patients, ustekinumab effectively treated moderate‐to‐severe psoriasis, and no new safety concerns have been reported.